×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:CPIX

Cumberland Pharmaceuticals Stock Forecast, Price & News

$2.10
+0.09 (+4.48%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.05
$2.14
50-Day Range
$1.93
$2.70
52-Week Range
$1.89
$7.51
Volume
2,704 shs
Average Volume
69,939 shs
Market Capitalization
$31.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPIX Stock Forecast (MarketRank)

Overall MarketRank

1.56 out of 5 stars

Medical Sector

987th out of 1,418 stocks

Pharmaceutical Preparations Industry

494th out of 679 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
Cumberland Pharmaceuticals logo

About Cumberland Pharmaceuticals (NASDAQ:CPIX)

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CPIX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CPIX
CUSIP
23077010
Employees
83
Year Founded
1999

Company Calendar

Last Earnings
5/10/2022
Today
6/24/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-3.51 million
Pretax Margin
-18.06%

Debt

Sales & Book Value

Annual Sales
$35.99 million
Cash Flow
$0.31 per share
Book Value
$2.88 per share

Miscellaneous

Free Float
8,335,000
Market Cap
$31.01 million
Optionable
Optionable
Beta
0.31

Social Links















Cumberland Pharmaceuticals Frequently Asked Questions

How has Cumberland Pharmaceuticals' stock price performed in 2022?

Cumberland Pharmaceuticals' stock was trading at $4.67 at the beginning of 2022. Since then, CPIX stock has decreased by 55.0% and is now trading at $2.10.
View the best growth stocks for 2022 here
.

When is Cumberland Pharmaceuticals' next earnings date?

Cumberland Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Cumberland Pharmaceuticals
.

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $11.18 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 13.81% and a negative trailing twelve-month return on equity of 5.57%.
View Cumberland Pharmaceuticals' earnings history
.

Who are Cumberland Pharmaceuticals' key executives?

Cumberland Pharmaceuticals' management team includes the following people:
  • Mr. A. J. Kazimi MBA, Founder, Chairman, Pres & CEO (Age 64, Pay $872.63k)
  • Mr. John Michael Hamm, Sr. Director of Fin. & Accounting and CFO (Age 65, Pay $304.91k)
  • Mr. Leo B. Pavliv R.Ph., Exec. VP of Operations & Chief Devel. Officer (Age 61, Pay $505.74k)
  • Mr. James Lowrance Herman, Exec. VP of National Accounts & Chief Compliance Officer (Age 67, Pay $320.65k)
  • Ms. Jean W. Marstiller, Sr. VP of Admin. Services & Corp. Sec. (Age 72)
  • Ms. Cindy B. Patton, Sr. Director of Field Marketing (Age 69)
  • Mr. Adam S. Mostafa, Managing Director (Age 42)
  • Mr. Todd M. Anthony, VP of Organizational Devel.
  • Ms. Erin Smith Gull, Sr. Corp. Relations Associate

What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO?

9 employees have rated Cumberland Pharmaceuticals CEO A. J. Kazimi on Glassdoor.com. A. J. Kazimi has an approval rating of 9% among Cumberland Pharmaceuticals' employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), CorMedix (CRMD) and Xeris Biopharma (XERS).

What is Cumberland Pharmaceuticals' stock symbol?

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

Who are Cumberland Pharmaceuticals' major shareholders?

Cumberland Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.34%), Dimensional Fund Advisors LP (4.27%), Vanguard Group Inc. (2.55%), Acadian Asset Management LLC (1.27%), State Street Corp (0.28%) and M Holdings Securities Inc. (0.07%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, A J Kazimi, Caroline Young, Gordon R Bernard, Joseph C Galante, Kenneth Krogulski, Martin E Cearnal, Martin E Cearnal and William Sumas.
View institutional ownership trends for Cumberland Pharmaceuticals
.

Which institutional investors are selling Cumberland Pharmaceuticals stock?

CPIX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, and Vanguard Group Inc..
View insider buying and selling activity for Cumberland Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Cumberland Pharmaceuticals stock?

CPIX stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, and M Holdings Securities Inc.. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Caroline Young, Joseph C Galante, Kenneth Krogulski, and Martin E Cearnal.
View insider buying and selling activity for Cumberland Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cumberland Pharmaceuticals' stock price today?

One share of CPIX stock can currently be purchased for approximately $2.10.

How much money does Cumberland Pharmaceuticals make?

Cumberland Pharmaceuticals (NASDAQ:CPIX) has a market capitalization of $31.01 million and generates $35.99 million in revenue each year. The specialty pharmaceutical company earns $-3.51 million in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Cumberland Pharmaceuticals have?

Cumberland Pharmaceuticals employs 83 workers across the globe.

When was Cumberland Pharmaceuticals founded?

Cumberland Pharmaceuticals was founded in 1999.

How can I contact Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The official website for Cumberland Pharmaceuticals is www.cumberlandpharma.com. The specialty pharmaceutical company can be reached via phone at (615) 255-0068, via email at [email protected], or via fax at 615-255-0094.

This page (NASDAQ:CPIX) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.